|
- LMP-420
- potent inhibitor of TNF-alpha, TNF-beta
- IC50 for human blood leukocytes approximately 50 nM
- inhibits TNF synthesis in human blood monocytes
- also inhibits TNF synthesis in human lymphocytes, neutrophils,
vascular endothelial cells, intestinal epithelial cells, mast cells, adipocytes, dendritic cells and alveolar macrophages
- inhibits TNF-alpha dependent replication of HIV-1 in cultured human cells
- inhibits TNF-alpha dependent replication
of Mycobacterium tuberculosis in cultured human cells (J. Immunol. 174:4203-4209, 2005)
- oral use for RA, Crohn's
Disease
- in preclinical development
|
|
- LMP-520
- inhibits expression of RANKL (TRANCE, OPGL), a potent activator of osteoclastogenesis and bone resorption,
in human immune cells and human osteosarcoma cells
- in preclinical development
|
